Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 13/20 | 0.73 |
| ▸ | EPAS1 | Q99814 | 13/20 | 0.73 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LPO | P22079 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387973 | 0.88 | HIF1A (0.86) | HIF1AEPAS1GPR84MAPTHTT | |
| SCHEMBL28220708 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| Mycalazal 14 SCHEMBL28220153 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL22342730 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL9385467 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL9385000 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL28220709 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL28220705 | 0.85 | HIF1A (1.00) | HIF1AEPAS1GPR84 | |
| SCHEMBL11173825 | 0.83 | — | — | |
| SCHEMBL12571386 | 0.82 | HIF1A (0.60) | HIF1AEPAS1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582904-B | 5-n-propyl-4-hydroxypyrrole-2-ketone derivative and preparation method and application thereof | 安徽农业大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-113582904-A | 5-n-propyl-4-hydroxypyrrole-2-ketone derivative and preparation method and application thereof | 安徽农业大学 | 2021-11-02 | — | — | CN | disclosed |
| WO-2021160139-A1 | 9,10-DIHYDROPHENANTHRENE COMPOUNDS AND USE THEREOF IN TREATMENT OF LIVER INJURY | 中国科学院上海药物研究所 | 2021-08-19 | — | — | WO | disclosed |
| EP-1753746-B8 | NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY | ROTTAPHARM SPA (IT) | 2012-02-15 | — | — | EP | disclosed |
| EP-1753746-B1 | NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY | ROTTAPHARM SPA (IT) | 2011-07-27 | — | — | EP | disclosed |
| US-7906501-B2 | Pyrrole derivatives with angiotensin II antagonist activity | ROTTAPHARM S.P.A. (IT) | 2011-03-15 | — | — | US | disclosed |
| US-20070244170-A1 | Novel Pyrrole Derivatives with Angiotensin II Antagonist Activity | ROTTAPHARM BIOTECH S.R.L. (IT) | 2007-10-18 | — | — | US | disclosed |
| EP-1753746-A2 | NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY | ROTTAPHARM S.P.A. (IT) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005105789-A2 | NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY | ROTTAPHARM S.P.A. (IT) | 2005-11-10 | — | — | WO | disclosed |
| US-5315013-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0323841-B1 | SUBSTITUTED PYRROLE, PYRAZOLE AND TRIAZOLE ANGIOTENSIN II ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5189048-A | Hypotensive agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| US-5093346-A | Hypotensive agents, congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-03 | — | — | US | disclosed |
| US-5081127-A | Hypotensive agents and treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-5043349-A | Hypotensive agents, treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-5015651-A | Triazole derivatives for treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0323841-A2 | Substituted pyrrole, pyrazole and triazole angiotensin II antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244170-A1 | Novel Pyrrole Derivatives with Angiotensin II Antagonist Activity | AGTR2, AGTR1, REN | HIF1A 1072/4885EPAS1 1395/4885MPO 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.